靶向CD38在多发性骨髓瘤中的分子动力学研究
该研究探讨了抗CD38抗体靶向多发性骨髓瘤细胞后膜动力学及后续事件。体外将人骨髓瘤细胞BF01与治疗性抗体共培养,进行基因表达谱分析,并检测微囊泡的基因和miRNA表达及表型。结果显示抗CD38抗体暴露引起CD38膜再分布、代谢相关基因上调及细胞周期相关基因下调,微囊泡表面CD73、CD39表达增加并携带PD-L1,且被FcR+细胞内化后自然杀伤细胞活化相关基因表达增加。
要点
- 抗CD38抗体暴露诱导骨髓瘤细胞CD38膜再分布及代谢基因上调。
- 抗体暴露细胞来源微囊泡表面CD73、CD39增加并携带PD-L1。
- 微囊泡被FcR+细胞内化后改变自然杀伤细胞功能基因表达。
核心结论
- 靶向CD38后骨髓瘤细胞可能通过微囊泡传递信号作为生存策略。
- 微囊泡表面酶 machinery 可产生耐受性腺苷。
- 微囊泡被FcR+细胞内化后引起显著功能修饰。
研究设计与样本
- 体外将人骨髓瘤细胞BF01与治疗性抗体或对照免疫球蛋白G共培养。
- 采用基因表达谱分析细胞及微囊泡的基因和miRNA表达。
- 对微囊泡进行表型特征分析。
主要发现
- 抗CD38抗体暴露导致BF01细胞CD38膜再分布。
- 代谢相关基因上调,细胞周期相关基因下调。
- 微囊泡CD73和CD39表达增加,存在PD-L1,miRNA显著上调或下调。
- 微囊泡积累于FcR+细胞周围。
- 自然杀伤细胞内化后活化及免疫应答相关基因表达显著增加,细胞周期相关基因下调。
临床怎么用
- 这些观察对通过靶向该机制及其后遗症改进抗CD38治疗性抗体具有相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple functions of CD38 need exploring to expand clinical application of anti-CD38 antibodies in multiple myeloma (MM). We investigated membrane dynamics of MM cells and subsequent events when CD38 is targeted by therapeutic antibodies. Human MM cells (BF01) were co-cultured in vitro with therapeutic antibody (or control immunoglobulin G) and analysed using gene expression profiling. Microvesicles from antibody-exposed cells were analysed for differential gene and microRNA (miRNA) expression, and for phenotypic characterisation. Exposure of BF01 cells to anti-CD38 antibody resulted in CD38 membrane redistribution, upregulation of metabolism-related genes and downregulation of genes involved in cell cycle processes. Microvesicles derived from antibody-exposed cells showed increased CD73 and CD39 expression, presence of programmed death-ligand 1 and significant up-/down-modulation of miRNAs. Microvesicles accumulated around immunoglobulin Fc receptor-positive (FcR+ ) cells. Upon internalisation, natural killer cells displayed significantly increased expression of genes related to activation and immune response, and downregulation of genes involved in the cell cycle. Cells may use microvesicles to transmit signals distally as part of a survival strategy. Microvesicles are equipped on their surface with enzymatic machinery leading to production of tolerogenic adenosine. Further, they are internalised in FcR+ cells with significant functional modifications. These observations have relevance for improving anti-CD38 therapeutic antibodies through targeting this mechanism and its sequelae.
引用
- Malavasi F, Faini AC, Morandi F, et al. Molecular dynamics of targeting CD38 in multiple myeloma. Br J Haematol. 2021. PMID: 33570193. doi:10.1111/bjh.17329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。